Search research articles
Contact Us
Filters
Showing results (401-410 of 424) with videos related to
Page
of 43
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
June 26, 2007
Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells
D Eugene Redmond, Kimberly B Bjugstad, Yang D Teng, et al.
Cancer Research
|
April 23, 2009
eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival
Jeremy R Graff, Bruce W Konicek, Rebecca L Lynch, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 18, 2004
Potent Kv1.3 inhibitors from correolide-modification of the C18 position
Jianming Bao, Shouwu Miao, Frank Kayser, et al.
Biorxiv : the Preprint Server for Biology
|
January 13, 2025
Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma
Kyosuke Shishikura, Jiasong Li, Yiming Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 17, 2010
Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers
Sriram Tyagarajan, Prasun K Chakravarty, Bishan Zhou, et al.
Biochemistry
|
June 12, 2002
Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties
William A Schmalhofer, Jianming Bao, Owen B McManus, et al.
Molecular Pharmacology
|
November 23, 2005
Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats
Richard M Brochu, Ivy E Dick, Jason W Tarpley, et al.
Science Advances
|
October 15, 2025
Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma
Kyosuke Shishikura, Jiasong Li, Yiming Chen, et al.
Molecular Cancer Therapeutics
|
December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity
Robert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
March 1, 2019
A Pragmatic Guide to Establishing Clinical Decision Support Governance and Addressing Decision Support Fatigue: a Case Study
Kensaku Kawamanto, Michael C Flynn, Polina Kukhareva, et al.
Page
of 43
Search research articles
Search
Showing results (401-410 of 424) with videos related to
Sort By:
Page
of 43
Proceedings of the National Academy of Sciences of the United States of America
|
June 26, 2007
Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells
D Eugene Redmond, Kimberly B Bjugstad, Yang D Teng, et al.
Cancer Research
|
April 23, 2009
eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival
Jeremy R Graff, Bruce W Konicek, Rebecca L Lynch, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 18, 2004
Potent Kv1.3 inhibitors from correolide-modification of the C18 position
Jianming Bao, Shouwu Miao, Frank Kayser, et al.
Biorxiv : the Preprint Server for Biology
|
January 13, 2025
Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma
Kyosuke Shishikura, Jiasong Li, Yiming Chen, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 17, 2010
Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers
Sriram Tyagarajan, Prasun K Chakravarty, Bishan Zhou, et al.
Biochemistry
|
June 12, 2002
Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties
William A Schmalhofer, Jianming Bao, Owen B McManus, et al.
Molecular Pharmacology
|
November 23, 2005
Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats
Richard M Brochu, Ivy E Dick, Jason W Tarpley, et al.
Science Advances
|
October 15, 2025
Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma
Kyosuke Shishikura, Jiasong Li, Yiming Chen, et al.
Molecular Cancer Therapeutics
|
December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity
Robert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
March 1, 2019
A Pragmatic Guide to Establishing Clinical Decision Support Governance and Addressing Decision Support Fatigue: a Case Study
Kensaku Kawamanto, Michael C Flynn, Polina Kukhareva, et al.
Page
of 43